ArticleMolecular pharmaceutics2017
Comparison of Avidin, Neutravidin, and Streptavidin as Nanocarriers for Efficient siRNA Delivery.
Article in Molecular pharmaceutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 77 citations in OpenAlex.
- Antibody Conjugation Strategies for Ultrasound Microbubbles: A Review of Bioconjugation Chemistry and Clinical Translation.Ultrasound in medicine & biology · 2026Review
- Photo-PISA DrivenACS sensors · 2025Article
- Multifunctional Peptide-Based Biohybrid for Targeted Reduction of Metastatic Breast Carcinoma-Associated Osteolysis.Journal of functional biomaterials · 2025Article
- Affinity-based controlled release of interleukin-4 from scaffolds via biotin-streptavidin interactions for immunomodulation.Journal of controlled release : official journal of the Controlled Release Society · 2025Article
- Mn-ferrite nanoparticles as promising magnetic tags for radiofrequency inductive detection and quantification in lateral flow assays.Nanoscale advances · 2024Article
- Photonic Crystal Surface Mode Real-Time Imaging of RAD51 DNA Repair Protein Interaction with the ssDNA Substrate.Biosensors · 2024Article
- Identifying molecular tags selectively retained on the surface of brain endothelial cells to generate artificial targets for therapy delivery.Fluids and barriers of the CNS · 2023Article
- An Analysis of the Biotin-(Strept)avidin System in Immunoassays: Interference and Mitigation Strategies.Current issues in molecular biology · 2023Review
- Simultaneous Sizing and Refractive Index Analysis of Heterogeneous Nanoparticle Suspensions.ACS nano · 2023Article
- Emerging micro-nanotechnologies for extracellular vesicles in immuno-oncology: from target specific isolations to immunomodulation.Lab on a chip · 2022Review
- Development of an Electrochemical CCL5 Chemokine Immunoplatform for Rapid Diagnosis of Multiple Sclerosis.Biosensors · 2022Article
- Distinct Binding Properties of Neutravidin and Streptavidin Proteins to Biotinylated Supported Lipid Bilayers: Implications for Sensor Functionalization.Sensors (Basel, Switzerland) · 2022Article
- How far is Lignin from being a biomedical material?Bioactive materials · 2022Review
- Nucleic acid strategies for infectious disease treatments: The nanoparticle-based oral delivery route.Frontiers in pharmacology · 2022Review
- Evaluation of the Targeting and Therapeutic Efficiency of Anti-EGFR Functionalised Nanoparticles in Head and Neck Cancer Cells for Use in NIR-II Optical Window.Pharmaceutics · 2021Article
- Two Novel PET Radiopharmaceuticals for Endothelial Vascular Cell Adhesion Molecule-1 (VCAM-1) Targeting.Pharmaceutics · 2021Article
- Targeted knockdown of the adenosine AMolecular therapy. Methods & clinical development · 2021Article
- Recent Advancements in Receptor Layer Engineering for Applications in SPR-Based Immunodiagnostics.Sensors (Basel, Switzerland) · 2021Review
- In vivo interactome profiling by enzyme-catalyzed proximity labeling.Cell & bioscience · 2021Review
- A Novel Targeted Therapy System for Cervical Cancer: Co-Delivery System of Antisense LncRNA of MDC1 and Oxaliplatin Magnetic Thermosensitive Cationic Liposome Drug Carrier.International journal of nanomedicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Protein-based drug delivery carrier has been one of the most employed modalities in biopharmaceuticals. In this study, we have compared avidin and its two analogues, neutravidin and streptavidin, as nanocarriers for the delivery of biotin-labeled siRNA with the help of biotinylated cholesterol (targeting ligand) and protamine (condensing agent). These proteins have similar binding affinity to biotin but substantial difference in their physical and chemical characteristics. Here, we have shown how these characteristics affect the size, cellular uptake, and activity of the avidin-based siRNA nanocomplex. In contrast to avidin and streptavidin nanocomplexes, neutravidin-based nanocomplex shows very low endosome entrapment and high cytoplasmic localization at extended times. High amount of the siRNA released in the cytoplasm by neutravidin-based nanocomplex at extended times (24 h) results in extensive and sustained PCBP2 gene silencing activity in HSC-T6 rat hepatic stellate cells. Neutravidin-based nanocomplex shows significantly low exocytosis in comparison to the streptavidin-based nanocomplex. Avidin-, neutravidin-, and streptavidin-based nanocomplexes are similar in size and had no significant cytotoxicity in transfected HSC-T6 cells or inflammatory cytokine induction in a whole blood assay. Compared to free siRNA, the neutravidin-based siRNA nanocomplex exhibits higher accumulation at 2 h in the liver of the rats with CCl
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.